The use of sildenafil in the treatment of persistent pulmonary hypertension of the newborn: A review of the literature

Current Pharmaceutical Design

Volumn 18, Issue 21, 2012, Pages 3034-3045

  Iacovidou, Nicoletta ^a   Syggelou, Aggeliki ^b   Fanos, Vassilios ^c   Xanthos, Theodoros ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Persistent pulmonary hypertension of newborn; Sildenafil

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHODIESTERASE V; PLACEBO; SILDENAFIL; VASCULOTROPIN; ZAPRINAST;

ARTIFICIAL VENTILATION; ASTHMA; BODY MASS; CAPILLARY DENSITY; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL MALFORMATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EXTRACORPOREAL CIRCULATION; EXTRACORPOREAL OXYGENATION; FETUS HYPOXIA; FOLLOW UP; GESTATIONAL AGE; HEART RIGHT LEFT SHUNT; HUMAN; HYPOTENSION; LUNG SHUNTING; LUNG VASCULAR RESISTANCE; MATERNAL SMOKING; MULTICENTER STUDY (TOPIC); NEWBORN; NONHUMAN; OXYGEN SATURATION; PERSISTENT PULMONARY HYPERTENSION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECOND TRIMESTER PREGNANCY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 84862620521     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023034     Document Type: Review

References (118)

1. Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am 2009; 56: 579-600.
2. Krishnan U. Management of pulmonary arterial hypertension in the neonatal unit. Cardiol Rev 2010; 18: 73-5.
3. Adatia I. Recent advances in pulmonary vascular disease. Curr Opin Pediatr 2002; 14: 292-7.
4. Hageman JR, Adams MA, Gardner TH. Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management. Am J Dis Child 1984; 138: 592-5
5. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105: 14-20.
6. Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin Perinatol 2005; 29: 8-14.
7. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342: 469-74.
8. Glass P, Wagner AE, Papero PH, et al. Neurodevelopmental status at age five years of neonates treated with extracorporeal membrane oxygenation. J Pediatr 1995; 127: 447-57.
9. Goldman AP, Tasker RC, Haworth SG, Sigston PE, Macrae DJ. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996; 98: 706-13.
10. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2007; 3: CD005494.
11. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 2007; 91: 283-90.
12. Greenough A, Roberton NRC. In: Greenough A, Milner AD, Roberton NRC, Ed. Neonatal Respiratory Disorders. USA: Arnold 1996; pp. 355-74.
13. France R. A review of fetal circulation and the segmental approach to fetal echocardiography. J Diagn Med Sonogr 2006; 22: 29-31.
14. Blackburn S. Placental, fetal, and transitional circulation revisited. J Perinat Neonatal Nurs 2006; 20: 290-4.
15. Lapointe A, Barrington KJ. Pulmonary hypertension and the asphyxiated newborn. J Pediatr 2011; 158: 19-24.
16. Greenough A, Khetriwal B. Pulmonary hypertension in the newborn. Paediatr Respir Rev 2005; 6: 111-6.
17. Haworth SG. Pulmonary endothelium in the perinatal period. Pharmacol Rep 2006; 58: 153-64.
18. Spillers J. PPHN: is sildenafil the new nitric? A review of the literature. Adv Neonatal Care 2010; 10: 69-74.
19. Nadeau S, Baribeau J, Janvier A, Perreault T. Changes in expression of vascular endothelial growth factor and its receptors in neonatal hypoxia-induced pulmonary hypertension. Pediatr Res 2005; 58: 199-205
20. Mathew R, Huang J, Gewitz MH. Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective. Cardiol Rev 2007; 15: 143-9.
21. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 2003; 107: 1195-201.
22. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120: 272-82.
23. Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001; 107: 519-23.
24. Van Marter LJ, Leviton A, Allred EN, et al. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics. 1996; 97: 658-63.
25. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006; 354:579-87.
26. Cullinane C, Cox PN, Silver MM. Persistent pulmonary hypertension of the newborn due to alveolar capillary dysplasia. Pediatr Pathol 1992;12(4):499-514.
27. Ban R, Ogihara T, Mori Y, Oue S, Ogawa S, Tamai H. Meconium Aspiration Delays Normal Decline of Pulmonary Vascular Resistance Shortly after Birth through Lung Parenchymal Injury. Neonatology 2010; 99 (4): 272-79.
28. Roberts JD Jr, Fineman JR, Morin FC 3rd, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336: 605-10.
29. Shah PS, Hellmann J, Adatia I. Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn. J Perinat Med 2004; 32: 168-70.
30. Lyrene RK, Welch KA, Godoy G, Philips JB 3rd. Alkalosis attenuates hypoxic pulmonary vasoconstriction in neonatal lambs. Pediatr Res 1985; 19: 1268-71.
31. Schreiber MD, Heymann MA, Soifer SJ. Increased arterial pH, not decreased PaCO2, attenuates hypoxia-induced pulmonary vasoconstriction in newborn lambs. Pediatr Res 1986; 20: 113-7.
32. HIFO Study Group. Randomised study of high frequency oscillatory ventilation in infants with severe respiratory distress. J Pediatr 1993; 122: 609-19.
33. Kinsella JP, Abman SH High-frequency oscillatory ventilation augments the response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn: Nitric Oxide Study Group. Chest 1998; 114(1 Suppl): 100S.
34. Dobyns EL, Anas NG, Fortenberry JD, et al. Interactive effects of high-frequency oscillatory ventilation and inhaled nitric oxide in acute hypoxemic respiratory failure in pediatrics. Crit Care Med 2002; 30: 2425-9.
35. Lotze A, Mitchell BR, Bulas DI, ZolaEM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr 1998; 132: 40-7.
36. Abman SH, Kinsella JP Surfactant use in the term neonate with hypoxemic respiratory failure. J Pediatr 1998; 133: 716-7.
37. Mehta S. Sildenafil for pulmonary arterial hypertension: exciting, but protection required. Chest 2003; 123: 989-92.
38. Kinsella JP, Truog WE, Walsh WF, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997; 131: 55-62.
39. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336: 597-604.
40. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998; 101: 325-34.
41. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2001; 3: CD000509.
42. Tworetzky W, Bristow J, Moore P, et al. Inhaled nitric oxide in neonates with persistent pulmonary hypertension. Lancet 2001; 357: 118-20.
43. Suguihara C. Treatment of persistent pulmonary hypertension of the newborn. J Pediatr (Rio J) 2001; 77: S17-24.
44. Macrae D. Drug therapy in persistent pulmonary hypertension of the newborn. Semin Fetal Neonatal Med 1997; 2: 49-58.
45. Truog WE, Castor CA, Sheffield MJ. Neonatal nitric oxide use: predictors of response and financial implications. J Perinatol 2003; 23: 128-32.
46. Sadiq HF, Mantych G, Benawra RS, Devaskar UP, Hocker JR. Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. J Perinatol 2003; 23: 98-103.
47. Macrae DJ, Field D, Mercier JC, et al. Inhaled nitric oxide therapy in neonates and children: reaching a European consensus. Intensive Care Med 2004; 30 (3): 372-80.
48. Goldman AP, Tasker RC, Haworth SG, Sigston PE, Macrae DJ. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996; 98: 706-13.
49. Kinsella JP, Abman SH. Inhaled nitric oxide: current and future uses in neonates. Semin Perinatol 2000; 24: 387-95.
50. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349: 2099-107.
51. Mestan KK, Marks JD, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 2005; 353: 23-32.
52. Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Preemie Inhaled Nitric Oxide Study. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005; 353: 13-22.
53. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2006; 25: CD000509.
54. Subhedar NV, Jauhari P, Natarajan R. Cost of inhaled nitric oxide therapy in neonates. Lancet 2002; 359: 1781-2.
55. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006; 117: 1077-83.
56. Kling J. Laboratory strategies for the year 2000 problem. Nat Biotechnol 1998; 16: 482-3.
57. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-73.
58. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994; 266: L536-43.
59. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-61.
60. Pauvert O, Salvail D, Rousseau E, Lugnier C, Marthan R, Savineau JP. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 2002; 63: 1763-72.
61. Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, Savineau JP. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br J Pharmacol 2003; 139: 513-22.
62. Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 2003; 36: 529-35.
63. Lakshminrusimha S, Porta NF, Farrow KN, et al. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 2009; 10:106-12.
64. Bassler D, Kreutzer K, McNamara P, Kirpalani H. Milrinone for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2010; 10: CD007802.
65. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298: 249-58.
66. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
67. Parker TA, Kinsella JP, Galan HL, Richter G, Abman SH. Prolonged infusions of estradiol dilate the ovine fetal pulmonary circulation. Pediatr Res 2000; 47: 89-96.
68. Parker TA, Afshar S, Kinsella JP, Ivy DD, Shaul PW, Abman SH. Effects of chronic estrogen receptor blockade on the pulmonary circulation in the late gestation ovine fetus. Am J Physiol 2001; 281:H1005-H1014.
69. MacRitchie AN, Jun SS, Chen Z, et al. Estrogen upregulates endothelial NO synthase gene expression in fetal pulmonary artery endothelium. Circ Res 1997; 81: 355-62.
70. Grover TR, Zenge JP, Parker TA, Abman SH. VEGF causes pulmonary vasodilation through activation of the PI 3-kinase-nitric oxide dependent pathway in the late gestation ovine fetus. Pediatr Res 2002; 52: 907-12.
71. Grover TR, Parker TA, Zenge JP, Markham NE, Abman SH. VEGF inhibition impairs endothelial function and causes pulmonary hypertension in the late gestation ovine fetus. Am J Physiol 2002; 284: L508-17.
72. Grover TR, Parker TA, Markham NE, Abman SH. rhVEGF treatment preserves pulmonary vasoreactivity and structure in an experimental model of pulmonary hypertension in fetal sheep. Am J Physiol 2005; 289: L315-21.
73. Lassus P, Turanlahti M, Heikkila P, et al. Pulmonary VEGF and flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 2001; 164: 1981-87.
74. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1993; 1178: 153-75.
75. Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB J 1993; 7: 328-38.
76. Sutherland EW. Studies on the mechanism of hormone action. Science 1972; 177: 401-8.
77. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-48.
78. Soderling SH, Bayuga SJ, Beavo JA. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998; 273: 15553-8.
79. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 1998; 246: 570-7.
80. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001; 108: 671-80.
81. Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 2002; 13: 29-35.
82. Braner DA, Fineman JR, Chang R, Soifer SJ. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol. 1993; 264: 252-8.
83. Cohen AH, Hanson K, Morris K, et al. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996; 97: 172-9.
84. Ichinose F, Erana-Garcia J, Hromi J, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001; 29: 1000-5.
85. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 1098-102.
86. Ryhammer PK, Shekerdemian LS, Penny DJ, Ravn HB. Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. Pediatr Res 2006; 59:762-66.
87. Tessler R, Wu S, Fiori R, Macgowan CK, Belik J. Sildenafil acutely reverses the hypoxic pulmonary vasoconstriction response of the newborn pig. Pediatr Res 2008; 64 (3): 251-5.
88. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53: 5S-12S.
89. Marsh CS, Marden B, Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol 2004; 88: 306-7.
90. Pierce CM, Petros AJ, Fielder AR. No evidence for severe retinopathy of prematurity following sildenafil. Br J Ophthalmol 2005; 89: 250.
91. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of longterm sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009; 154: 379-84.
92. Gamboa D, Robbins D, Saba Z. Bleeding after circumcision in a newborn receiving sildenafil. Clin Pediatr (Phila) 2007; 46: 842-3.
93. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91: 307-10.
94. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000; 92: 1702-12.
95. Shekerdemian LS, Ravn HB, Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 2004; 55: 413-8.
96. Roberts RJ, Weesner KM, Bucher JR. Oxygen-induced alterations in lung vascular development in the newborn rat. Pediatr Res 1983; 17: 368-75.
97. Wilson WL, Mullen M, Olley PM, Rabinovitch M. Hyperoxiainduced pulmonary vascular and lung abnormalities in young rats and potential for recovery. Pediatr Res 1985; 19: 1059-67.
98. Shaffer SG, O'Neill D, Bradt SK, Thibeault DW. Chronic vascular pulmonary dysplasia associated with neonatal hyperoxia exposure in the rat. Pediatr Res 1987; 21: 14-20.
99. Randell SH, Mercer RR, Young SL. Neonatal hyperoxia alters the pulmonary alveolar and capillary structure of 40-day-old rats. Am J Pathol 1990; 136: 1259-66.
100. Han RN, Buch S, Tseu I, et al. Changes in structure, mechanics, and insulin-like growth factor-related gene expression in the lungs of newborn rats exposed to air or 60% oxygen. Pediatr Res 1996; 39: 921-9.
101. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thébaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 2005; 172: 750-6.
102. Baquero H, Neira F, Venegas ME, Sola A, Soliz A. Outcome at 18 months of age after sildenafil therapy for refractory neonatal hypoxemia. E-PAS 2005; 57: 2119.
103. Herrea J, Castillo R, Concha E, Soliz A. Oral sildenafil treatment as an alternative to inhaled NO therapy for persistent pulmonary hypertension of the newborn. In: E-PAS 2006:59:3724.3.
104. Daga S. R, Verma B., Valvi C. Sildenafil for pulmonary hypertension in non-ventilated preterm babies. The Internet Journal of Pediatrics and Neonatology 2008; 8: 1.
105. Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009; 155: 841-7.
106. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006; 174: 1042-7.
107. Juliana AE, Abbad FC. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. Eur J Pediatr. 2005; 164: 626-9.
108. Simiyu DE, Okello C, Nyakundi EG, Tawakal AH. Sildenafil in management of persistent pulmonary hypertension of the newborn: report of two cases. East Afr Med J 2006; 83: 337-40.
109. Reid LM. Lung growth in health and disease. Br J Dis Chest 1984; 78: 113-34.
110. Antunes MJ, Greenspan JS, Cullen JA, Holt WJ, Baumgart S, Spitzer AR. Prognosis with preoperative pulmonary function and lung volume assessment in infants with congenital diaphragmatic hernia. Pediatrics 1995; 96: 1117-22.
111. Thibeault DW, Haney B. Lung volume, pulmonary vasculature, and factors affecting survival in congenital diaphragmatic hernia. Pediatrics 1998; 101: 289-95.
112. German JC, Bartlett RH, Gazzaniga AB, Huxtable RF, Amlie R, Sperling DR. Pulmonary artery pressure monitoring in persistent fetal circulation (PFC). J Pediatr Surg 1977; 12: 913-9.
113. Haugen SE, Linker D, Eik-Nes S, et al. Congenital diaphragmatic hernia: determination of the optimal time for operation by echocardiographic monitoring of the pulmonary arterial pressure. J Pediatr Surg 1991; 26: 560-2.
114. Bos AP, Tibboel D, Koot VC, Hazebroek FW, Molenaar JC. Persistent pulmonary hypertension in high-risk congenital diaphragmatic hernia patients: incidence and vasodilator therapy. J Pediatr Surg 1993; 28: 1463-5.
115. Ivy DD, Kinsella JP, Ziegler JW, Abman SH. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998; 115: 875-82.
116. Tworetzky W, Bristow J, Moore P, et al. Inhaled nitric oxide in neonates with persistent pulmonary hypertension. Lancet 2001; 357: 118-20.
117. Keller RL, Hamrick SE, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med 2004; 5: 184-7.
118. Filan PM, McDougall PN, Shekerdemian LS. Combination pharmacotherapy for severe neonatal pulmonary hypertension J Paediatr Child Health 2006; 42: 219-20.